NasdaqGS:TLRYPharmaceuticals
A Look at Tilray (NasdaqGS:TLRY) Valuation Following U.S. Cannabis Reform Prospects and European Expansion Deal
Tilray Brands (NasdaqGS:TLRY) has been pulling in attention from every corner of the investing world lately. The spark? Momentum around marijuana’s possible reclassification to Schedule III, proposed by Donald Trump, is building in Washington and signaling a meaningful shift that could reshape the entire U.S. cannabis sector. Adding to that, Tilray’s own recent news of partnering with Italian pharma group Molteni to expand its medical cannabis footprint in Europe has also attracted market...